Brief Report

HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial

Jessica Marie Louise Fogel, Sarah E. Hudelson, San San Ou, Stephen Hart, Carole Wallis, Mariza G. Morgado, Shanmugam Saravanan, Srikanth Tripathy, Laura Hovind, Estelle Piwowar-Manning, Devin Sabin, Marybeth McCauley, Theresa Gamble, Xinyi C. Zhang, Joseph J. Eron, Joel E. Gallant, Johnstone Kumwenda, Joseph Makhema, Nagalingeswaran Kumarasamy, Suwat Chariyalertsak & 13 others James Hakim, Sharlaa Badal-Faesen, Victor Akelo, Mina C. Hosseinipour, Breno R. Santos, Sheela V. Godbole, Jose H. Pilotto, Beatriz Grinsztejn, Ravindre Panchia, Kenneth H. Mayer, Ying Q. Chen, Myron S. Cohen, Susan Eshleman

Research output: Contribution to journalArticle

Abstract

Early initiation of antiretroviral treatment (ART) reduces HIV transmission and has health benefits. HIV drug resistance can limit treatment options and compromise use of ART for HIV prevention. We evaluated drug resistance in 85 participants in the HIV Prevention Trials Network 052 trial who started ART at CD4 counts of 350-550 cells per cubic millimeter and failed ART by May 2011; 8.2% had baseline resistance and 35.3% had resistance at ART failure. High baseline viral load and less education were associated with emergence of resistance at ART failure. Resistance at ART failure was observed in 7 of 8 (87.5%) participants who started ART at lower CD4 cell counts.

Original languageEnglish (US)
Pages (from-to)304-309
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Volume72
Issue number3
DOIs
StatePublished - Jul 1 2016

Fingerprint

Drug Resistance
Treatment Failure
HIV
CD4 Lymphocyte Count
Insurance Benefits
Viral Load
Education

Keywords

  • ART failure
  • early ART
  • HIV
  • HPTN 052
  • resistance

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Brief Report : HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial. / Fogel, Jessica Marie Louise; Hudelson, Sarah E.; Ou, San San; Hart, Stephen; Wallis, Carole; Morgado, Mariza G.; Saravanan, Shanmugam; Tripathy, Srikanth; Hovind, Laura; Piwowar-Manning, Estelle; Sabin, Devin; McCauley, Marybeth; Gamble, Theresa; Zhang, Xinyi C.; Eron, Joseph J.; Gallant, Joel E.; Kumwenda, Johnstone; Makhema, Joseph; Kumarasamy, Nagalingeswaran; Chariyalertsak, Suwat; Hakim, James; Badal-Faesen, Sharlaa; Akelo, Victor; Hosseinipour, Mina C.; Santos, Breno R.; Godbole, Sheela V.; Pilotto, Jose H.; Grinsztejn, Beatriz; Panchia, Ravindre; Mayer, Kenneth H.; Chen, Ying Q.; Cohen, Myron S.; Eshleman, Susan.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 72, No. 3, 01.07.2016, p. 304-309.

Research output: Contribution to journalArticle

Fogel, JML, Hudelson, SE, Ou, SS, Hart, S, Wallis, C, Morgado, MG, Saravanan, S, Tripathy, S, Hovind, L, Piwowar-Manning, E, Sabin, D, McCauley, M, Gamble, T, Zhang, XC, Eron, JJ, Gallant, JE, Kumwenda, J, Makhema, J, Kumarasamy, N, Chariyalertsak, S, Hakim, J, Badal-Faesen, S, Akelo, V, Hosseinipour, MC, Santos, BR, Godbole, SV, Pilotto, JH, Grinsztejn, B, Panchia, R, Mayer, KH, Chen, YQ, Cohen, MS & Eshleman, S 2016, 'Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial', Journal of Acquired Immune Deficiency Syndromes, vol. 72, no. 3, pp. 304-309. https://doi.org/10.1097/QAI.0000000000000951
Fogel, Jessica Marie Louise ; Hudelson, Sarah E. ; Ou, San San ; Hart, Stephen ; Wallis, Carole ; Morgado, Mariza G. ; Saravanan, Shanmugam ; Tripathy, Srikanth ; Hovind, Laura ; Piwowar-Manning, Estelle ; Sabin, Devin ; McCauley, Marybeth ; Gamble, Theresa ; Zhang, Xinyi C. ; Eron, Joseph J. ; Gallant, Joel E. ; Kumwenda, Johnstone ; Makhema, Joseph ; Kumarasamy, Nagalingeswaran ; Chariyalertsak, Suwat ; Hakim, James ; Badal-Faesen, Sharlaa ; Akelo, Victor ; Hosseinipour, Mina C. ; Santos, Breno R. ; Godbole, Sheela V. ; Pilotto, Jose H. ; Grinsztejn, Beatriz ; Panchia, Ravindre ; Mayer, Kenneth H. ; Chen, Ying Q. ; Cohen, Myron S. ; Eshleman, Susan. / Brief Report : HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial. In: Journal of Acquired Immune Deficiency Syndromes. 2016 ; Vol. 72, No. 3. pp. 304-309.
@article{c579df4423544eba85bafa378c2b8dcf,
title = "Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial",
abstract = "Early initiation of antiretroviral treatment (ART) reduces HIV transmission and has health benefits. HIV drug resistance can limit treatment options and compromise use of ART for HIV prevention. We evaluated drug resistance in 85 participants in the HIV Prevention Trials Network 052 trial who started ART at CD4 counts of 350-550 cells per cubic millimeter and failed ART by May 2011; 8.2{\%} had baseline resistance and 35.3{\%} had resistance at ART failure. High baseline viral load and less education were associated with emergence of resistance at ART failure. Resistance at ART failure was observed in 7 of 8 (87.5{\%}) participants who started ART at lower CD4 cell counts.",
keywords = "ART failure, early ART, HIV, HPTN 052, resistance",
author = "Fogel, {Jessica Marie Louise} and Hudelson, {Sarah E.} and Ou, {San San} and Stephen Hart and Carole Wallis and Morgado, {Mariza G.} and Shanmugam Saravanan and Srikanth Tripathy and Laura Hovind and Estelle Piwowar-Manning and Devin Sabin and Marybeth McCauley and Theresa Gamble and Zhang, {Xinyi C.} and Eron, {Joseph J.} and Gallant, {Joel E.} and Johnstone Kumwenda and Joseph Makhema and Nagalingeswaran Kumarasamy and Suwat Chariyalertsak and James Hakim and Sharlaa Badal-Faesen and Victor Akelo and Hosseinipour, {Mina C.} and Santos, {Breno R.} and Godbole, {Sheela V.} and Pilotto, {Jose H.} and Beatriz Grinsztejn and Ravindre Panchia and Mayer, {Kenneth H.} and Chen, {Ying Q.} and Cohen, {Myron S.} and Susan Eshleman",
year = "2016",
month = "7",
day = "1",
doi = "10.1097/QAI.0000000000000951",
language = "English (US)",
volume = "72",
pages = "304--309",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Brief Report

T2 - HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial

AU - Fogel, Jessica Marie Louise

AU - Hudelson, Sarah E.

AU - Ou, San San

AU - Hart, Stephen

AU - Wallis, Carole

AU - Morgado, Mariza G.

AU - Saravanan, Shanmugam

AU - Tripathy, Srikanth

AU - Hovind, Laura

AU - Piwowar-Manning, Estelle

AU - Sabin, Devin

AU - McCauley, Marybeth

AU - Gamble, Theresa

AU - Zhang, Xinyi C.

AU - Eron, Joseph J.

AU - Gallant, Joel E.

AU - Kumwenda, Johnstone

AU - Makhema, Joseph

AU - Kumarasamy, Nagalingeswaran

AU - Chariyalertsak, Suwat

AU - Hakim, James

AU - Badal-Faesen, Sharlaa

AU - Akelo, Victor

AU - Hosseinipour, Mina C.

AU - Santos, Breno R.

AU - Godbole, Sheela V.

AU - Pilotto, Jose H.

AU - Grinsztejn, Beatriz

AU - Panchia, Ravindre

AU - Mayer, Kenneth H.

AU - Chen, Ying Q.

AU - Cohen, Myron S.

AU - Eshleman, Susan

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Early initiation of antiretroviral treatment (ART) reduces HIV transmission and has health benefits. HIV drug resistance can limit treatment options and compromise use of ART for HIV prevention. We evaluated drug resistance in 85 participants in the HIV Prevention Trials Network 052 trial who started ART at CD4 counts of 350-550 cells per cubic millimeter and failed ART by May 2011; 8.2% had baseline resistance and 35.3% had resistance at ART failure. High baseline viral load and less education were associated with emergence of resistance at ART failure. Resistance at ART failure was observed in 7 of 8 (87.5%) participants who started ART at lower CD4 cell counts.

AB - Early initiation of antiretroviral treatment (ART) reduces HIV transmission and has health benefits. HIV drug resistance can limit treatment options and compromise use of ART for HIV prevention. We evaluated drug resistance in 85 participants in the HIV Prevention Trials Network 052 trial who started ART at CD4 counts of 350-550 cells per cubic millimeter and failed ART by May 2011; 8.2% had baseline resistance and 35.3% had resistance at ART failure. High baseline viral load and less education were associated with emergence of resistance at ART failure. Resistance at ART failure was observed in 7 of 8 (87.5%) participants who started ART at lower CD4 cell counts.

KW - ART failure

KW - early ART

KW - HIV

KW - HPTN 052

KW - resistance

UR - http://www.scopus.com/inward/record.url?scp=84976315930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976315930&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000000951

DO - 10.1097/QAI.0000000000000951

M3 - Article

VL - 72

SP - 304

EP - 309

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 3

ER -